{"filings":[{"id":94092,"accession_number":"0001612630-26-000048","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","2.03","2.02","7.01","9.01"],"status":"ready","headline":"JYNT Q1 revenue up 13%, net income up 34%; credit covenant default waived","event_type":"earnings","confidence":"high","bullets":["Revenue $14.8M (+13% YoY); net income from continuing ops $1.1M vs loss $506K prior year.","Consolidated diluted EPS $0.09 (vs $0.06); Adj EBITDA from consolidated ops $3.5M (+22%).","Credit default waived for fixed charge coverage ratio violation; JPM line extended to Aug 2029, $20M undrawn.","System-wide comp sales -4.2%; total clinic count 943 (down 17 vs Q4 2025).","Refranchised 45 clinics to Elite Chiro Group for $2.3M; repurchased 137K shares for $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":14820233.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94091,"accession_number":"0001612630-26-000039","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"The Joint Corp. sells 45 Southern California clinics for $2.3M, moves to pure franchisor model","event_type":"other_material","confidence":"high","bullets":["45 clinics sold to Elite Chiro Group for $2.3M; 13 closed on April 27, 2026.","32 clinics under management service agreement until lease assignments are completed.","After deal, corporate clinics drop to just 3 out of 960 total locations.","Part of 'The Joint 2.0' shift to capital-light, pure-play franchisor model.","Elite Chiro Group led by Gadi Emein and Michael Aminpour."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94090,"accession_number":"0001612630-26-000036","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Joint Corp. agrees to sell 45 Southern California clinics to Elite Chiro Group for $2.3M","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $2.3M, includes $150k non-refundable down payment; remainder paid into escrow.","Sale covers 45 company-owned/managed clinics in Southern California; clinics will convert to franchise agreements.","Buyer Elite Chiro Group also gets non-exclusive development rights for 10 additional clinics.","Closing for each clinic conditioned on lease assignment; proceeds allocated per clinic schedule.","Seller retains six other California clinics (Midtown Crossing, Inglewood, West Hollywood, Santa Monica, Mission Viejo, San Marcos)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106210,"accession_number":"0001612630-26-000018","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q4 revenue $15.2M (+3.1% YoY); FY2025 net income $2.9M; guides FY2026 system-wide sales $519-552M","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $15.2M (+3.1% YoY); net income from continuing ops $937K vs $909K.","FY2025 total revenue $54.9M; consolidated net income $2.9M vs net loss $5.8M in 2024.","Adjusted EBITDA from consolidated ops $13.0M (+13.9% YoY); FY2026 guidance $12.5-13.5M.","Refranchised 41 clinics in FY2025; 27 more in process; targets pure-play franchisor model.","Repurchased 1.3M shares for $11.3M in FY2025; $5.7M remaining on $12M buyback program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106208,"accession_number":"0001612630-26-000008","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K/A","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Joint Corp. agrees to nominate activist investor Jefferson Gramm to board","event_type":"other_material","confidence":"high","bullets":["Letter agreement with Bandera Partners LLC requires company to include Jefferson Gramm in director slate for 2026 annual meeting.","Bandera restricted from acquiring beneficial ownership beyond 3,937,296 shares until termination date.","Agreement remains in effect until earlier of 30 days before 2027 nomination deadline or January 21, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106209,"accession_number":"0001612630-26-000004","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Joint Corp. agrees to nominate activist investor Jefferson Gramm to board at 2026 annual meeting","event_type":"other_material","confidence":"high","bullets":["Company will nominate Jefferson Gramm (Bandera Partners) and recommend his election at 2026 annual meeting.","Bandera agrees to standstill and not buy additional shares beyond current 3,937,296 JYNT shares until Jan 21, 2027.","Agreement includes voting commitments and transfer restrictions; termination date earlier of Jan 21, 2027 or 30 days before 2027 meeting.","Current beneficial ownership of Bandera is 3,937,296 shares; no additional purchases allowed except director grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122491,"accession_number":"0001612630-25-000074","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Joint Corp signs $1.5M APA for 22 SE clinics, terminates $4.5M APA for 45 CA clinics","event_type":"m_and_a","confidence":"high","bullets":["Sold 22 clinics in VA, NC, SC for aggregate purchase price of $1,482,800; buyers are existing franchisees/operators.","Buyers will pay $100K down payment; remaining balance via promissory notes; lease assignments required for closing.","Delivered termination notice on Dec 11 for prior APA to sell 45 Southern California clinics for $4.5M due to buyer's failure to meet conditions.","No penalties for termination; company reiterates belief in franchise community expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122490,"accession_number":"0001612630-25-000066","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","2.02","7.01","8.01","9.01"],"status":"ready","headline":"Joint Corp Q3 net income turns positive to $855K; sells 45 clinics for $4.5M; adds $12M buyback","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $13.4M (+6% YoY); consolidated net income $855K vs loss of $3.2M in Q3 2024.","Adjusted EBITDA from continuing ops $1.4M vs $262K in Q3 2024; consolidated adjusted EBITDA $3.3M (+36%).","Agreed to sell 45 Southern California clinics for $4.5M via asset purchase agreement (terms still being negotiated).","Board authorized additional $12M for stock repurchase program; 540K shares bought for $5M since program start.","Lowered FY2025 system-wide sales guidance to $530-534M and comp sales to (1)% to 0% from prior low-single-digit growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":39728545.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122489,"accession_number":"0001612630-25-000060","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"The Joint Corp. to refranchise all company clinics; credit maturity extended to Aug 2027","event_type":"other_material","confidence":"high","bullets":["Consent to refranchise 100% of company-owned/managed clinics to franchisees by Dec 31, 2025.","Revolving credit maturity extended to August 31, 2027; loan balance required to be $0 before/after each sale.","Each clinic disposition must be for fair value and at least 75% cash; fair value may be $0 for negative-earning clinics.","Amendment with JPMorgan Chase updates definitions and disposition allowances; no other material changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139189,"accession_number":"0001612630-25-000044","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Former CFO Jake Singleton to receive $171,959 severance, accrued PTO, and $15K under separation agreement","event_type":"leadership","confidence":"high","bullets":["CFO Jake Singleton's employment ended June 9, 2025; separation agreement signed Aug 22, 2025, includes general release of claims.","Separation benefits: lump-sum base salary of $171,958.50 (6 months), accrued PTO of $36,193.99, additional $15,000, plus up to 6 months COBRA.","No accelerated vesting of equity awards; terms governed by existing award agreements and equity plans.","Confidentiality, non-disparagement, and arbitration provisions apply; restrictive covenant agreement remains in effect.","Company agrees to provide neutral reference (job title and dates of employment) and directs two executives not to make knowingly false statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139188,"accession_number":"0001612630-25-000021","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q2 rev $13.3M +5%, narrows loss; cuts FY system-wide sales guidance to $530-550M","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $13.3M (+5% YoY); consolidated net income $93K vs loss $3.6M; net loss from continuing ops $990K vs loss $1.7M.","Adjusted EBITDA from continuing ops improved to $88K from loss $380K; consolidated Adj EBITDA up 52% to $3.2M.","Refranchised 37 clinics for $11.2M, acquired NW regional developer territory for $2.8M; franchised now 92% of 967 clinics.","Cuts FY 2025 system-wide sales guidance to $530-550M (from $550-570M); comp sales now low-single digit vs mid-single digit; raises consolidated Adj EBITDA guidance.","Announced restatement of 2024 10-K and Q1 2025 10-Q for non-cash impairment errors; no impact on Adj EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":26347860.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139187,"accession_number":"0001612630-25-000015","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"The Joint Corp. to restate FY2024 and Q1 2025 results due to overestimated impairment charges by ~$2.2M","event_type":"other_material","confidence":"high","bullets":["Expects to reduce 2024 net loss by ~$2.2M and increase carrying value of assets held for sale by ~$2.2M.","For Q1 2025, expects net income increase of ~$0.5M; cumulative carrying value increase of ~$2.7M.","No impact on Adjusted EBITDA or cash for either period.","Expects material weakness in internal controls and that disclosure controls were ineffective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139186,"accession_number":"0001612630-25-000009","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"The Joint Corp. closes sale of 31 clinics for $11.13M, acquires NW region RD rights","event_type":"m_and_a","confidence":"high","bullets":["Sold 31 company-owned clinics in AZ/NM to Joint Ventures, LLC for $11.13M (includes $8.3M cash).","Acquired regional developer rights for Northwest region (46 franchised clinics, 30 future sites).","Acquired RD rights generated $855,000 in royalties/fees in trailing 12 months ended March 31, 2025.","Pro forma shows net income from continuing operations of $88,979 for Q1 2025 vs prior loss of $506,021.","Transaction expected to reduce commission obligations and increase operating margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156742,"accession_number":"0001612630-25-000006","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"The Joint sells 31 clinics for $11.07M, acquires NW region rights, refranchises 5 clinics","event_type":"m_and_a","confidence":"high","bullets":["Sale of 31 corporate clinics to Joint Ventures, LLC for $11.07M; buyer to own 96 clinics total.","The Joint acquires regional developer rights for Northwest Region (46 existing+30 future sites).","Refranchised 5 Kansas City clinics to Chiro 93, LLC led by Dr. Clint Morrow.","Transaction expected to close on or before June 30, 2025; company to reduce RD commissions.","Company says deal improves profitability, tracks to become largest pure-play chiropractic franchise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156741,"accession_number":"0001628280-25-030452","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp. names Scott J. Bowman CFO, replacing Jake Singleton","event_type":"leadership","confidence":"high","bullets":["Scott J. Bowman appointed CFO effective June 10, 2025; Jake Singleton separated June 9, 2025.","Bowman previously CFO at Leslie's, Dave & Buster's, Hibbett; 30+ years experience.","Employment agreement: $390,000 annual base salary; $250,000 initial equity grant under 2024 Incentive Stock Plan.","CEO Sanjiv Razdan cites Bowman's transformation and growth expertise for disciplined execution.","Bowman notes focus on multiphase strategy to reignite growth, reduce overhead, improve profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156740,"accession_number":"0001628280-25-029505","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"The Joint Corp. adds director Sandi Karrmann and authorizes $5M stock buyback","event_type":"other_material","confidence":"high","bullets":["Appointed Sandra R.A. Karrmann as director; board increases to eight; she will chair Compensation Committee.","Karrmann is an experienced HR executive from Kimberly-Clark, Tenet Healthcare, and Yum! Restaurants International.","Board approved up to $5M stock repurchase program, expected to begin August 2025, through June 3, 2027.","Repurchases may be made on open market or privately; no obligation to buy specific amount.","CEO says buyback reflects confidence in long-term strategy and refranchising program; stock undervalued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156739,"accession_number":"0001171843-25-003380","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Joint Corp. shareholders elect all seven director nominees, approve say-on-pay, ratify auditor at annual meeting","event_type":"other","confidence":"high","bullets":["All seven Board nominees elected, including Matthew Rubel, Ronald DaVella, and Sanjiv Razdan.","Advisory vote on executive compensation approved with 10.66M for, 0.51M against.","Ratification of BDO USA, P.C. as independent auditor for FY2025 ratified with 12.74M for.","Broker non-votes of ~2.06M shares on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}